Antibody density on rat red cells determines the rate of activation of the complement component C1
- PMID: 2996908
- DOI: 10.1002/eji.1830151003
Antibody density on rat red cells determines the rate of activation of the complement component C1
Abstract
It is a common observation that there is variability in the rate of activation of C1, the first component of complement, when bound to immune complexes. The cause of this variation has been investigated with experiments designed to assess separately the effect of antibody, antigen and C1 density. Using 125I-labeled C1 and a rat monoclonal antibody specific for the class I antigen, it has been found that the rate of activation is primarily dependent on antibody density on the cell surface and not on antigen or C1 density. This finding supports the suggestion that direct contact between the C1r2C1s2 subcomponent of C1 and antibody may be required for potentiation of C1 activation.
Similar articles
-
Antibody-independent activation of C1. I. Differences in the mechanism of C1 activation by nonimmune activators and by immune complexes: C1r-independent activation of C1s by cardiolipin vesicles.J Immunol. 1987 Mar 15;138(6):1864-70. J Immunol. 1987. PMID: 3029222
-
Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q.J Immunol. 1986 Jul 1;137(1):255-62. J Immunol. 1986. PMID: 3486914
-
Activation of the first component of complement, C1, by a monoclonal antibody recognizing the C chain of C1q.J Immunol. 1984 Feb;132(2):804-8. J Immunol. 1984. PMID: 6606678
-
C1 subcomponent complexes: basic and clinical aspects.Behring Inst Mitt. 1993 Dec;(93):292-8. Behring Inst Mitt. 1993. PMID: 8172579 Review.
-
Activation of the first component of complement.Annu Rev Immunol. 1987;5:21-42. doi: 10.1146/annurev.iy.05.040187.000321. Annu Rev Immunol. 1987. PMID: 3036181 Review. No abstract available.
Cited by
-
Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies.Cancers (Basel). 2020 Oct 19;12(10):3041. doi: 10.3390/cancers12103041. Cancers (Basel). 2020. PMID: 33086644 Free PMC article. Review.
-
Fc microparticles can modulate the physical extent and magnitude of complement activity.Biomater Sci. 2017 Feb 28;5(3):463-474. doi: 10.1039/c6bm00608f. Biomater Sci. 2017. PMID: 28067347 Free PMC article.
-
Enhancing Fc-mediated effector functions of monoclonal antibodies: The example of HexaBodies.Immunol Rev. 2024 Nov;328(1):456-465. doi: 10.1111/imr.13394. Epub 2024 Sep 14. Immunol Rev. 2024. PMID: 39275983 Free PMC article. Review.
-
Complement System Part I - Molecular Mechanisms of Activation and Regulation.Front Immunol. 2015 Jun 2;6:262. doi: 10.3389/fimmu.2015.00262. eCollection 2015. Front Immunol. 2015. PMID: 26082779 Free PMC article. Review.
-
Epithelial tight junction proteins as potential antibody targets for pancarcinoma therapy.Cancer Immunol Immunother. 2005 May;54(5):431-45. doi: 10.1007/s00262-004-0613-x. Epub 2004 Oct 16. Cancer Immunol Immunother. 2005. PMID: 15750830 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources